Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NovaBay Pharmaceuticals, Inc. (NBY)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.2909-0.0041 (-1.39%)
At close: 03:59PM EST
0.2900 -0.00 (-0.31%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Downside Breakout

Downside Breakout

Previous Close0.2950
Open0.2950
Bid0.2910 x 1400
Ask0.2915 x 1000
Day's Range0.2850 - 0.3150
52 Week Range0.2800 - 1.7900
Volume491,673
Avg. Volume961,424
Market Cap13.078M
Beta (5Y Monthly)3.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NBY

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NovaBay Pharmaceuticals, Inc.
    Analyst Report: Abbott LaboratoriesAbbott Laboratories is a diversified healthcare company that develops, manufactures and markets a wide range of medical products and services. Its main product lines are nutritionals for adults and infants, diagnostic systems, vascular implants, cardiac rhythm management products, and diabetes care products.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Business Wire

    NovaBay Pharmaceuticals Announces Changes to Its Board of Directors

    EMERYVILLE, Calif., January 28, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces the appointments of Audrey Kunin, M.D. and Julie Garlikov to the NovaBay Board of Directors. Dr. Kunin is a recognized leader in the skincare product industry and has served as NovaBay’s Chief Product Officer since its acquisition in November 20

  • Business Wire

    NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks

    EMERYVILLE, Calif., January 20, 2022--NovaBay Pharmaceuticals donates 2.5 million KN95 protective masks.

  • Business Wire

    NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

    EMERYVILLE, Calif., January 20, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company"), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces that its Special Meeting of Stockholders held on December 17, 2021, as adjourned to and reconvened on January 14, 2022, has been further adjourned until January 31, 2022 at 11:00 a.m. Pacific time in order to provide

Advertisement
Advertisement